Damien Bailly, president of established markets at Astellas, discusses why partnerships and collaborations are a critical organizational—and wider ecosystem—imperative in ensuring that patients have access to the medicines they need.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses why their drug isn't experiencing the same supply issues as the bigger names in the space.

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Greater Than One’s Chief Strategy Officer, Andrew Bast, shares his takeaways from 2024 Rare Disease Summit in Philadelphia, PA.

Users will be able to access DeepScribe’s documentation platform through AWS.

The latest news for pharma industry insiders.

The program is designed to tackle issues related to the high cost of prescription medication.

Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.

Why this role provides a critical ‘boot camp’ for future pharma leaders.

Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.

Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses factors that are contributing to ongoing supply issues and if prices for these therapies are coming down anytime soon.

The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.

Leverage priorities in preclinical business planning.

The latest news for pharma industry insiders.

This facility is the first of four facilities to be built in the area.

New methods allow the antiseizure treatment to be crushed and mixed with water for oral suspension or for use through a nasogastric tube.

Treatment was initially approved in 2017 for the same indication in children aged 12 and up.

Resurgence offers a mixed bag as capital crunch continues for many.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses how a personalized approach in obesity treatment can benefit access.

Is it possible to win in Asia’s private market?

Ellenor discusses key points from the recent SCOPE presentation.

The meeting is scheduled for May in Switzerland.

The latest news for pharma industry insiders.

Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas' research and development efforts.